Acetyl-L-carnitine as a putative candidate for the treatment of stress-related psychiatric disorders: Novel evidence from a zebrafish model.


Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
15 05 2019
Historique:
received: 11 01 2019
revised: 12 03 2019
accepted: 17 03 2019
pubmed: 29 3 2019
medline: 22 1 2020
entrez: 29 3 2019
Statut: ppublish

Résumé

Stress-related psychiatric disorders are mental conditions that affect mood, cognition and behavior and arise because of the impact of prolonged stress on the central nervous system (CNS). Acetyl-L-carnitine (ALC) is an acetyl ester of L-carnitine that easily crosses the blood-brain barrier and was recently found to be decreased in patients with major depressive disorder. ALC plays a role in energy metabolism and is widely consumed as a nutritional supplement to improve physical performance. In this study, our objective was to evaluate the effects of ALC treatment (0.1 mg/L, 10 min) for 7 days on behavior and oxidative stress in zebrafish subjected to unpredictable chronic stress (UCS) protocol. Behavioral outcomes were assessed in the novel tank test, and parameters of oxidative status (lipid peroxidation and antioxidant defenses) were evaluated in the brain using colorimetric methods. According to our previous findings, UCS increased anxiety-like behavior and lipid peroxidation, while it decreased non-protein thiol levels and superoxide dismutase activity. However, ALC reversed the anxiety-like behavior and oxidative damage in stressed animals, while it was devoid of effect in control animals. Although our data reinforce the neuroprotective potential of ALC in the treatment of psychiatric disorders related to stress, further investigations are required to clarify its mechanisms of action and confirm its efficacy.

Identifiants

pubmed: 30917915
pii: S0028-3908(19)30103-0
doi: 10.1016/j.neuropharm.2019.03.024
pii:
doi:

Substances chimiques

Antioxidants 0
Acetylcarnitine 6DH1W9VH8Q

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

145-152

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Matheus Marcon (M)

Programa de Pós-graduação em Neurociências, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Ricieri Mocelin (R)

Programa de Pós-graduação em Neurociências, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Diogo L de Oliveira (DL)

Programa de Pós-graduação em Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Alex Sander da Rosa Araujo (AS)

Programa de Pós-graduação em Fisiologia, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Ana P Herrmann (AP)

Programa de Pós-graduação em Farmacologia e Terapêutica, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Angelo Piato (A)

Programa de Pós-graduação em Neurociências, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Programa de Pós-graduação em Farmacologia e Terapêutica, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Zebrafish Neuroscience Research Consortium (ZNRC), Slidell, LA, USA. Electronic address: angelopiato@ufrgs.br.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH